FDA approves Roche genetic test as an alternative to pap smear for cervical cancer screening
WASHINGTON - Federal health regulators have cleared a genetic test from Roche as the first U.S.-approved alternative to the pap smear, the decades-old mainstay of cervical cancer screening.
The Food and Drug Administration approved Roche's cobas HPV test to detect the human papillomavirus, or HPV, in women 25 and older. HPV causes nearly all cases of cervical cancer. Such DNA-based tests have been used for several years to confirm results from the pap tests. But Thursday's decision means Roche can now market the test as a stand-alone option for cervical cancer screening, without the pap test.
The decision comes despite pushback from a number of women's health groups, who warned regulators that approving the DNA test as an alternative to pap testing could lead to confusion, higher costs and overtreatment.
Read more Business News
- BC likes to stay activeKelowna
- First Ebola case in the USWorld
- Distracted driving talesVernon / N. Okanagan
- Canadian dies in avalancheWorld
|QHR Technologies Inc||1.26||+0.03|
|Anavex Life Sciences||0.184||-0.001|
|Copper Mountain Mining||2.42||-0.10|
|Sunrise Resources Ltd||0.065||+0.045|
|Mission Ready Services||0.32||-0.02|
Part 2 of 2 to read Part 1, click here. 5. Dial down your vacations. New York is out. Maybe Buffalo. For West coast, maybe Seattle instead of Hawaii. Use sites like Airbnb (aribnb.ca) to find ch...
Niche food producer “Sweets from the Earth” thrives using innovation, uniqueness and an unwavering focus on quality. A neighbour’s stew turned Ilana Kadonoff off meat at the age of s...
Recently I had the privilege of working alongside André Voskuil, a local guru in the world of Alternative Financing. André has quite the reputation in the world of direct investments as ...